Major study does not confirm increased risk of death reported by US trial

Major study does not confirm increased risk of death reported by US trial

Preliminary results of the ADVANCE Study, a large diabetes trial involving over 11,000 high risk patients with type 2 diabetes, show no evidence of an increased risk of death among patients receiving intensive treatment to lower blood glucose.
In the ADVANCE study, the intensive blood glucose lowering program aimed to reduce HbA1c to below 6.5%. In view of the unexpected report from the ACCORD trial (see news item 27th February), the investigators in the ADVANCE study looked at their data to assess whether there was any evidence to support the suggestion that intensive blood glucose lowering may increase mortality.